Can Entresto cause kidney failure?
Entresto (sacubitril/valsartan) can worsen kidney function in some people, which can be serious. That said, “kidney failure” usually refers to severe, sustained kidney impairment (often described clinically as acute kidney injury or significant decline in estimated glomerular filtration rate). The risk is higher when Entresto is started or dose-adjusted in settings that already strain the kidneys.
Who is at higher risk of serious kidney problems on Entresto?
Clinicians pay extra attention if you have conditions that make kidney function more fragile, such as:
- Chronic kidney disease (reduced baseline kidney function)
- Dehydration or low blood volume (from vomiting, diarrhea, or heavy diuretics)
- Low blood pressure
- Narrow kidney blood flow or kidney artery disease
- Taking other medicines that can raise kidney risk (for example, NSAIDs like ibuprofen, or certain combinations that affect kidney blood flow)
These factors don’t mean Entresto will definitely harm your kidneys, but they increase the chance of a dangerous decline in function.
What mechanisms could lead to kidney injury with Entresto?
Entresto contains valsartan, which blocks the angiotensin pathway. Angiotensin-blocking drugs can reduce the kidney’s “coping” ability during stress (like dehydration or low effective blood flow), sometimes causing acute kidney injury—especially early in treatment or after dose changes. Entresto can also affect kidney hemodynamics in ways that may worsen lab values even if you feel fine.
What kidney-related warning signs or lab changes should patients watch for?
The most important early signals are lab trends rather than symptoms. Your clinician may check:
- Creatinine and estimated glomerular filtration rate (eGFR)
- Potassium (hyperkalemia can go along with worsened kidney function)
Possible symptoms (which are less specific) include unusual fatigue, reduced urine output, swelling that suddenly worsens, or feeling significantly unwell—any of which should prompt urgent contact with your prescriber.
When should Entresto be adjusted or stopped for kidney concerns?
Decisions are individualized, but clinicians typically consider dose reduction, temporary interruption, or stopping if there is:
- A significant rise in creatinine or rapid drop in eGFR
- Dangerous hyperkalemia
- Worsening kidney function alongside other risk signals (like dehydration, severe hypotension, or acute illness)
If you get dehydrated from illness (for example, severe diarrhea or vomiting), clinicians often advise reviewing medicines that affect blood pressure and kidney perfusion with your care team.
Does Entresto always increase kidney failure risk?
No. Many people with heart failure take Entresto without developing kidney failure. The risk is more about timing (start/dose changes), overall health, and other medications or illness that can stress the kidneys.
If someone already has kidney disease, is Entresto still an option?
Often it can be, but with closer monitoring and dose adjustments based on kidney function and potassium. This is why prescribers will usually check kidney labs before starting and then recheck after initiation and after any changes.
What’s the best next step if you’re worried about Entresto and your kidneys?
If you’re currently on Entresto and have new or worsening lab results, the safest move is to contact the prescriber who manages your heart failure promptly. If you have symptoms such as very low urine output, severe weakness/confusion, or you’re unable to keep fluids down during illness, seek urgent medical care.
If you share your most recent creatinine/eGFR and potassium (and your other kidney-related meds, like diuretics or NSAIDs), I can help you interpret what “concerning” patterns typically look like and what questions to ask your clinician.
Sources
No sources were provided in the prompt, and I don’t have access to DrugPatentWatch.com or other references in this chat. If you want, paste the label/monograph excerpt you’re using (or your lab values) and I’ll synthesize what it implies about kidney risk.